Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Cardiac magnetic resonance angiography (CMRA)
Cardiac magnetic resonance angiography (CMRA) is an imaging modality that provides a mechanism to assess cardiac or vascular anatomy, function, perfusion, and tissue characteristics in a highly reproducible manner, during a single examination. CMRA can also be used to determine coronary artery patency in adults with coronary artery disease (CAD), and as a diagnostic modality for patients with suspected anomalous coronary anatomy.
Status: Decision completed
Why is CMRA being reviewed?
There have been a number of CMRA technological advances in the past decade; however, its accuracy and clinical utility for diagnosis in routine clinical practice are unclear. This topic was selected because of medium-level concerns about the safety and efficacy of CMRA and high-level concern about costs. The objective of the health technology assessment (HTA) is to evaluate the diagnostic validity (i.e., accuracy), clinical utility (i.e., effectiveness), safety, and cost-effectiveness of CMRA in adults or children with known or suspected coronary vessel anomalies or congenital heart disease.
Primary Criteria Ranking
- Safety = Medium
- Efficacy = High
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2021) |
Assessment timeline
- Draft key questions published: March 15, 2021
- Public comment period: March 16 to March 30, 2021
- Final key questions published: April 12, 2021
- Draft report published: September 7, 2021
- Public comment period: September 7 to October 6, 2021
- Final report published: October 20, 2021
- HTCC public meeting: November 19, 2021